This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.
Hypertrophic Cardiomyopathy
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
-
UC San Diego Altman Clinical and Translational Research Institute - Center for Clinical Research, La Jolla, California, United States, 92093
University of California San Francisco, San Francisco, California, United States, 94117
Emory University, Atlanta, Georgia, United States, 30322
Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115
Mayo Clinic, Rochester, Minnesota, United States, 55905
The Christ Hospital Physicians - The Ohio Heart and Vascular Center, Cincinnati, Ohio, United States, 45219
Cleveland Clinic, Cleveland, Ohio, United States, 44195
Oregon Health & Science University, Portland, Oregon, United States, 97239
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104
Houston Methodist Hospital, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 75 Years
ALL
No
Tenaya Therapeutics,
2032-08